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Abstract: The metabolic score for insulin resistance (METS-IR) is a novel noninsulin-based marker
for assessing the risk of insulin resistance and cardiometabolic risk. However, whether METS-IR
is associated with incident ischemic heart disease (IHD) risk is not well known. Therefore, we
aimed to investigate the longitudinal effect of METS-IR on incident IHD risk in a large cohort of
Korean adults without diabetes. Data were assessed from 17,943 participants without diabetes from
the Health Risk Assessment Study (HERAS) and Korea Health Insurance Review and Assessment
(HIRA) data. The participants were divided into four groups according to METS-IR index quartiles:
(ln ((2 × fasting plasma glucose) + triglyceride) × body mass index)/(ln (HDL-cholesterol)). We
prospectively assessed hazard ratios (HRs) with 95% confidence intervals (CIs) for IHD using
multivariate Cox proportional hazard regression models over a 50-month period. During the follow-
up period, 332 participants (1.9%) developed IHD. HRs of IHD for METS-IR quartiles 1–4 were
1.00, were 1.62 (95% CI 1.04–2.53), 1.87 (95% CI 1.20–2.91), and 2.11 (95% CI 1.35–3.30), respectively,
after adjusting for potential confounding variables. A higher METS-IR precedes future IHD among
Koreans without diabetes. Moreover, compared with metabolic syndrome, METS-IR had a better
predictive value for IHD.
Keywords: metabolic score for insulin resistance; cardiometabolic risk; longitudinal study; ischemic
heart disease
1. Introduction
Cardiovascular diseases (CVDs) are the leading cause of death worldwide in 2019,
and the majority of deaths from CVD are caused by ischemic heart disease (IHD), with
most deaths occurring between the ages of 30 and 70 [1,2]. IHD is a major cause of rising
medical expenses, and the early onset of IHD in the aging population is important because
it is one of the factors that lowers the quality of life and increases the burden of social
medical expenses [3].
Insulin resistance is defined as an impaired biological response to insulin actions in
the insulin-responsive tissues and is considered key to the mechanism of metabolic syn-
drome [4]. The prevalence of insulin resistance has increased globally, and it is known to
be from 15.5 to 46.5% of adults [5]. Previous studies have suggested that insulin resistance
is significantly related to the development and progression of coronary atherosclerosis
and adverse plaque characteristics and is a major risk factor for cardiovascular diseases
via pathophysiological mechanisms [4]. Insulin resistance is also the common pathophys-
iology of prehypertension and prediabetes [6]. Moreover, some studies have found that
nondiabetic individuals with IHD tend to exhibit poorer prognosis than diabetic patients
without IHD [7,8]. Thus, early detection of insulin resistance in the early stages of IHD is
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necessary in, for example, non-diabetes patient with metabolic risks and with a high risk of
IHD, prevent other diseases and reduce the socioeconomic burden for IHD.
Recently, the metabolic score for insulin resistance (METS-IR), a higher concordance
with the hyperinsulinemic-euglycemic clamp, has been developed, and it has been reported
that METS-IR is strongly associated with hypertension and predictive abilities for type 2
diabetes [9,10]. However, to our knowledge, information is limited to the longitudinal
association between METS-IR and incident IHD. Therefore, we prospectively investigated
the association between METS-IR and IHD incidence in a large-scale, community-dwelling
Korean population without diabetes using the Health Risk Assessment Study (HERAS)
and Korea Health Insurance Review and Assessment Service (HIRA) database.
2. Materials and Methods
2.1. Study Population
This cohort study was derived from the HERAS-HIRA datasets, aiming to explore
surrogate markers for IHD among Korean without diabetes [11]. The cohort consisted of
20,530 subjects who visited the Health Promotion Center at the Yonsei University Gangnam
Severance Hospital for health examinations between November 2006 and June 2010. We
excluded 1590 participants who had previously been diagnosed with IHD or ischemic
stroke, had a previous diagnosis of type 2 diabetes, or a fasting plasma glucose (FPG)
level ≥ 126 mg/dL [12]. In addition, patients who met at least one of the following criteria
were excluded: aged < 20 years and with current use of dyslipidemia medication or aspirin
(n = 997). Consequently, 17,943 individuals (9152 men and 8791 women) were included in
the final analysis (Figure 1).
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Kaplan–Meier curves were used to assess the cumulative incidence of IHD. The log-rank 
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justing for potential confounding variables. All analyses were performed using SAS ver-
sion 9.4 software (SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided, 
and statistical significance was set at p < 0.05. 
  
Figure 1. Flowchart for the selection of study participants.
Each participant completed a questionnaire describing their lifestyle and medical
history. Smoking status was classified as never smoker, ex-smoker, or current smoker.
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A regular alcohol drinker was defined as a person who consumed more than 140 g of
alcohol per week. Regular exercise was defined as moderate physical activity three or
more times per week. Bodyweight and height were measured in light indoor clothing
and no shoes to the nearest 0.1 kg and 0.1 cm. Body mass index (BMI) was calculated as
weight divided by height squared (kg/m2). Systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were measured in the sitting position after 10 min of rest using a
standard mercury sphygmomanometer (Baumanometer, W.A. Baum Co Inc., Copiague,
NY, USA). The mean arterial pressure was calculated from the SBP and DBP. Hypertension
was defined as an SBP ≥ 140 mmHg, DBP ≥ 90 mmHg, or current hypertension medication
use [13]. Impaired fasting glucose was defined as FPG levels between 100 mg/dL and
125 mg/dL [14]. Metabolic syndrome was defined as the presence of ≥3 of the follow-
ing risk factors: obesity with BMI ≥ 25.0 kg/m2, elevated SBP ≥ 130 mmHg, elevated
DBP ≥ 85 mmHg, or using an antihypertensive medication; high FPG levels ≥ 100 mg/dL
or using diabetes medication; triglyceride (TG) levels ≥ 150 mg/dL; and high-density
lipoprotein cholesterol (HDL-C) < 40 mg/dL and < 50 mg/dL for men and women, respec-
tively [15]. An estimated glomerular filtration rate (eGFR) was calculated as 186.3 × (serum
creatinine − 1.154) × (age − 0.203) × 0.742 (if female) [16]. METS-IR was calculated as
(ln ((2 × FPG) + TG) × BMI)/(ln (HDL-C)) [9].
2.2. Study Outcomes
The primary outcome was IHD, which consisted of angina pectoris (ICD-10 code I20)
or acute myocardial infarction (ICD-10 code I21) that occurred after enrollment into the
study. To define baseline and study outcomes, we linked a personal 13-digit identification
number assigned to each participant by the HIRA between 1 November 2006 and 31
December 2010.
2.3. Statistical Analysis
METS-IR values were categorized into quartiles as follows: Q1 (≤28.9), Q2 (29.0–33.2),
Q3 (33.3–37.9), and Q4 (≥38.0). All data are presented as mean ± standard deviation or
percentage. We have used box plots and the Kolmogorov–Smirnov test to evaluate the
distribution of the variables. According to the METS-IR quartiles, the baseline charac-
teristics of the study population were compared using an analysis of variance (ANOVA)
model for continuous variables and Pearson’s chi-squared test for categorical variables.
Kaplan–Meier curves were used to assess the cumulative incidence of IHD. The log-rank
test was used to determine whether the distribution of cumulative IHD incidence differed
among the groups. In multivariate analysis, after setting the lowest METS-IR value quartile
as a reference group, hazard ratios (HRs) and 95% confidence intervals (CIs) for incident
IHD were calculated using the Cox proportional hazards regression model after adjust-
ing for potential confounding variables. All analyses were performed using SAS version
9.4 software (SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided, and
statistical significance was set at p < 0.05.
3. Results
Table 1 shows the baseline characteristics of the study population (n = 17,943; 9152 men
and 8791 women) according to the METS-IR quartiles. The mean age and BMI of the study
population were 44.7 ± 10.5 years and 23.3 ± 3.1 kg/m2, respectively. The mean FPG
concentration was 91.1 ± 9.8 mg/dL, the mean triglycerides level was 122 ± 83 mg/dL,
and the mean METS-IR index value was 33.8 ± 6.5. The prevalence of impaired fasting
glucose and metabolic syndrome was 17.2% and 11.5%, respectively. Mean BMI, mean
arterial pressure, total cholesterol, and high-sensitivity C-reactive protein (hsCRP) values
were highest, and mean HDL-C levels and eGFR were lowest in the highest METS-IR index
quartile group. The greatest proportion of current smokers and alcohol drinkers were
members of the fourth METS-IR index quartile. The higher METS-IR index groups had a
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significantly elevated cumulative incidence of IHD over a 50-month period that followed
the baseline survey (log-rank test, p < 0.001) (Figure 2).









n = 4559 p Value
1 Post Hoc 2
METS-IR ≤28.9 29.0–33.2 33.3–37.9 ≥38.0
Age (years) 40.7 ± 10.4 45.4 ± 10.3 46.7 ± 10.1 46.0 ± 10.1 <0.001 a,b,c,d,e,f
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Mean arterial pressure (mmHg) 84 ± 10 89 ± 10 93 ± 10 97 ± 10 <0.001 a,b,c,d,e,f
Fasting plasma glucose (mg/dL) 86.3 ± 8.4 89.9 ± 8.5 92.4 ± 9.2 95.6 ± 10.3 <0.001 a,b,c,d,e,f
Total cholesterol (mg/dL) 180 ± 31 186 ± 32 191 ± 33 197 ± 34 <0.001 a,b,c,e,f
Triglyceride (mg/dL) 73 ± 26 95 ± 39 125 ± 57 193 ± 117 <0.001 a,b,c,d,e,f
HDL-cholesterol (mg/dL) 65 ± 11 56 ± 10 49 ± 8 43 ± 7 <0.001 a,b,c,d,e,f
C-reactive protein (mg/L) 0.8 ± 2.7 1.2 ± 3.5 1.6 ± 4.6 1.9 ± 4.0 <0.001 a,b,c,d,e,f
eGFR (mL/min/1.73 m2) 86.6 ± 14.7 83.9 ± 13.3 82.7 ± 13.0 82.0 ± 12.6 <0.001 a,b,c,d,e
Current smoker (%) 14.6 20.5 26.6 37.4 <0.001 -
Alcohol drinking (%) 35.1 40.5 48.2 51.6 <0.001 -
Regular exercise (%) 26.5 33.6 33.2 27.8 <0.001 -
Hypertension (%) 6.3 13.5 23.3 35.5 <0.001 -
Impaired fasting glucose (%) 5.6 12.0 19.4 31.5 <0.001 -
Metabolic syndrome (%) 0.1 1.5 7.5 36.5 <0.001 -
1 p-values were calculated using one-way ANOVA or Pearson’s chi-square test. 2 Post hoc analysis with the Bonferroni method: a, Q1
versus Q2; b, Q1 versus Q3; c, Q1 versus Q4; d, Q2 versus Q3; e, Q2 versus Q4; and f, Q3 versus Q4.




Figure 2. Kaplan–Meier plots indicating the cumulative ischemic heart disease. 
Table 2 shows the results of the multivariate Cox proportional hazards regression 
analysis for the prediction of IHD according to the METS-IR index quartile. A total of 332 
individuals (1.9%, 332/17,943) developed IHD during the study period. The incidence rate 
(per 1000 person-years) of IHD increased proportionally as the METS-IR index quartile 
increased. Compared with the first METS-IR index quartile, the HRs of incident IHD for 
the second, third, and fourth quartiles increased in a dose-dependent manner. The HRs of 
incident IHD were 1.62 (95% CI 1.04–2.53), 1.87 (95% CI 1.20–2.91), and 2.11 (95% CI 1.35–
3.30) for the second, third, and fourth METS-IR index quartiles, respectively, after adjust-
ing for age, sex, smoking status, alcohol intake, physical activity, mean arterial blood pres-
sure, total cholesterol, hsCRP, eGFR, and hypertension medication. 
Table 2. Hazard ratios and 95% CIx for new-onset IHD according to METS-IR quartiles. 
 METS-IR Quartiles 
 Q1 Q2 Q3 Q4 p Trend 
New cases of ischemic heart 
disease, n 
33 76 102 121  
Mean follow-up, years 2.3 ± 1.0 2.4 ± 1.1 2.4 ± 1.1 2.4 ± 1.1  
Person-years of follow-up 10,311 10,646 10,521 10,853  
Incidence rate/1000 person-
years 3.2 7.1 9.7 11.1  
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Table 2 sho s the results of the multivariate Cox proportional hazards regression
analysis for the prediction of IHD according to the METS-IR index quartile. A total of
332 individuals (1.9%, 332/17,943) developed IHD during the study period. The incidence
rate (per 1000 person-years) of IHD increased proportionally as the METS-IR index quartile
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increased. Compared with the first METS-IR index quartile, the HRs of incident IHD
for the second, third, and fourth quartiles increased in a dose-dependent manner. The
HRs of incident IHD were 1.62 (95% CI 1.04–2.53), 1.87 (95% CI 1.20–2.91), and 2.11
(95% CI 1.35–3.30) for the second, third, and fourth METS-IR index quartiles, respectively,
after adjusting for age, sex, smoking status, alcohol intake, physical activity, mean arterial
blood pressure, total cholesterol, hsCRP, eGFR, and hypertension medication.
Table 2. Hazard ratios and 95% CIx for new-onset IHD according to METS-IR quartiles.
METS-IR Quartiles
Q1 Q2 Q3 Q4 p Trend
New cases of ischemic heart disease, n 33 76 102 121
Mean follow-up, years 2.3 ± 1.0 2.4 ± 1.1 2.4 ± 1.1 2.4 ± 1.1
Person-years of follow-up 10,311 10,646 10,521 10,853
Incidence rate/1000 person-years 3.2 7.1 9.7 11.1
Model 1 1.00 (reference) 1.60 (1.06–2.41) 1.91 (1.28–2.86) 2.25 (1.51–3.35) <0.001
Men 1.00 (reference) 1.55 (0.80–3.04) 2.00 (1.06–3.77) 2.26 (1.21–4.24) 0.031
Women 1.00 (reference) 1.62 (0.95–2.75) 1.71 (0.97–3.00) 2.13 (1.20–3.79) 0.080
Model 2 1.00 (reference) 1.65 (1.06–2.58) 2.00 (1.30–3.01) 2.34 (1.52–3.59) 0.001
Men 1.00 (reference) 1.47 (0.75–2.88) 1.78 (0.94–3.37) 2.14 (1.14–4.03) 0.050
Women 1.00 (reference) 1.73 (0.95–3.15) 2.05 (1.10–3.81) 2.05 (1.06–3.96) 0.111
Model 3 1.00 (reference) 1.63 (1.04–2.54) 1.94 (1.25–3.01) 2.22 (1.43–3.47) 0.004
Men 1.00 (reference) 1.42 (0.72–2.80) 1.70 (0.89–3.25) 2.04 (1.07–3.87) 0.095
Women 1.00 (reference) 1.78 (0.98–3.25) 2.10 (1.12–3.93) 2.11 (1.06–4.20) 0.103
Model 4 1.00 (reference) 1.62 (1.04–2.53) 1.87 (1.20–2.91) 2.11 (1.35–3.30) 0.010
Men 1.00 (reference) 1.39 (0.70–2.73) 1.61 (0.84–3.07) 1.90 (1.00–3.61) 0.169
Women 1.00 (reference) 1.80 (0.99–3.28) 2.07 (1.10–3.88) 2.07 (1.04–4.12) 0.116
Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, smoking status, alcohol intake, and physical activity. Model 3: adjusted
for age, sex, smoking status, alcohol intake, physical activity, mean arterial blood pressure, total cholesterol, high-sensitivity C-reactive
protein, and eGFR. Model 4: adjusted for age, sex, smoking status, alcohol intake, physical activity, mean arterial blood pressure, total
cholesterol, high-sensitivity C-reactive protein, eGFR, and hypertension medication.
Using a pairwise comparison of receiver operating characteristic (ROC) analyses of
incident IHD, the areas under the ROC curves (AUC) of METS-IR data were significantly
higher than those of metabolic syndrome (p < 0.001), whereas the number of metabolic
syndrome was not significantly different. The estimated optimal cut-off values to predict
IHD were determined using Youden’s index, with results varying between 0.104 and 0.202.
The cut-off value of 31.1, with 81.9 % sensitivity and 38.3 % specificity for METS-IR, seems
to be a surrogate marker with a useful screening performance in our study (Table 3).
Table 3. METS-IR versus MetS and the number of MetS components for predicting IHD.
Pairwise Comparison of AUC
Difference 95% CI p Value
METS-IR vs. MetS 0.069 0.04 to 0.9 <0.001
METS-IR vs. N of MetS components 0.004 −0.02 to 0.03 0.733
N of MetS components vs. MetS 0.064 0.04 to 0.09 <0.001









METS-IR 81.9 38.3 >31.1 0.620 0.202 <0.001
Men 84.4 25.4 >32.3 0.554 0.097 0.005
Women 71.9 55.5 >30.9 0.657 0.274 <0.001
MetS 22.7 88.7 >0 0.552 0.104 <0.001
N of MetS components 78.6 39.0 >0 0.616 0.176 <0.001
AUC, area under the receiver operating characteristic curve; MetS, metabolic syndrome; N, number.
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4. Discussion
Among a community-based population of Korean adults without diabetes, we found
that elevated METS-IR was positively and independently associated with IHD incidence
in this longitudinal cohort study that included a 50-month follow-up. We also found that
METS-IR outperformed the prediction for IHD compared to metabolic syndrome.
Insulin resistance is described as a low response to insulin action in adipose tissue,
skeletal muscles, and liver. In the early stage of insulin resistance, only compensatory
hyperinsulinemia appears, and then, in the late stage, insulin resistance can cause the
development of dyslipidemia, hypertension, CVDs, etc. [4]. According to pathophysiologi-
cal mechanisms, insulin is known as the headstream of metabolic syndrome [4]. Insulin
resistance is involved in atherosclerosis, and hyperglycemia plays an important role in
the early stages of atherosclerosis, which is the main risk factor for developing IHD [17].
Previous studies also revealed that insulin resistance is associated with an increased risk of
CVD in nondiabetic patients [18,19]. Thus, early detection of insulin resistance in adults
at risk for future IHD is important for prevention and slowing the progression of IHD.
HOMA-IR is the most widely used method to evaluate the degree of insulin resistance [20].
However, it is likely to cause bias depending on the use of insulin assay, including cal-
ibration setup in the kit and conversions between units [21,22]. Recently, METS-IR, a
non-insulin-based insulin resistance, has been reported to have strong predictive abilities
for CVD risk [9,10,23,24]. To date, there has been no research on the correlation between
METS-IR and IHD.
Metabolic syndrome is said to consist of a cluster of heart disease risk factors, including
low HDL-C, high triglyceride, impaired carbohydrate metabolism, central obesity, and
high blood pressure [25]. An important feature of metabolic syndrome is insulin resistance,
characterized in nondiabetics by increased levels of serum insulin, and it has been suggested
that insulin itself is atherogenic [26]. Many epidemiological studies have indicated that
metabolic syndrome is associated with IHD and used to predict the risk of IHD in the
clinical field [27,28]. Our results are consistent with the findings of previous prospective
studies showing that metabolic syndrome was associated with an increased incidence of
IHD or CVDs [29,30]. However, the findings of our study showed that the METS-IR had
higher predictive power than MetS as a dichotomous classification for IHD. Some possible
explanations for this observed association deserve consideration. First, the diagnostic
criteria for metabolic syndrome are inconsistent across countries. For example, some
studies reported that metabolic syndrome based on Japanese criteria had a weak association
with the risk of IHD and predicted IHD less effectively because of the difference in the
cutoff values of waist circumference of Japanese metabolic syndrome diagnosis criteria [28].
Second, recent studies have shown that the prognostic role of metabolic syndrome does
not increase more than the sum of its components [29,31]. Metabolic syndrome not only
increases cardiovascular risk, but also each of its components is associated with an increased
risk of CVD [30,32–34]. Some studies found that an increased FPG level is a less competent
indicator of cardiovascular outcomes [35]. Moreover, the role of BMI in CVDs remains
debatable because different studies have presented conflicting results [36,37]. However,
studies have demonstrated that triglyceride, HDL-C, glucose intolerance, and insulin
levels expectedly correlate best with insulin resistance [38]. It was reported in Korea that
obesity is strongly associated with insulin resistance, and a combination of the triglyceride
glucose (TyG) index and BMI was superior to other modified TyG indices for predicting
insulin resistance in adults [39]. Previous studies have reported that the TyG index may
be a useful predictive marker of CVD [11,40]. In addition, triglycerides and HDL-C
have each been found to be more predictive of CVD than total cholesterol in the Asia
Pacific region [41]. Thus, METS-IR may be regarded as a more favorable predictor of
IHD than metabolic syndrome because the combination of triglyceride, BMI, FPG, and
HDL-C may lead to a better explanation of the cardiometabolic risk for CVD outcome.
Third, some studies have suggested that the risk of cardiovascular disease increases with
an increase in the number of metabolic syndrome components [42,43]. Previous studies
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have suggested that the incidence of coronary heart disease and incident CVD risk shows
a progressive increase from one to five metabolic syndrome components [44,45]. Some
studies found that the risk of developing CVD increased significantly with increasing
number of metabolic syndrome components, and this trend persisted even after adjusting
for sex, drinking status, and family history of hypertension, diabetes, and CVD; participants
with ≥3 metabolic syndrome components were at three times a higher risk of developing
CVD than those without any components [42,43]. We also found that the number of
components of metabolic syndrome was more highly predictive of IHD than metabolic
syndrome as a dichotomous classification among individuals without diabetes. Thus,
consideration of the number of risk components of metabolic syndrome may be more
informative than metabolic syndrome as a dichotomous classification when determining
the risk of IHD.
A significant strength of the work was that we conducted a cohort study using many
Korean individuals linked to HIRA data from the universal coverage system in Korea.
However, the HERAS-HIRA dataset assessed only newly developed IHD and not coronary
angioplasty, myocardial resuscitation, or sudden death. Additionally, some individuals
with diabetes may have been included in the study population because hemoglobin A1c
and 2-h postprandial glucose tests were not available at the baseline.
5. Conclusions
An elevated METS-IR predicts future IHD among community-dwelling Koreans with-
out diabetes and is superior to metabolic syndrome as a helpful predictive indicator of IHD.
Accordingly, higher METS-IR may be a useful additional measure to assess cardiometabolic
risk in nondiabetic adults at the preclinical stage.
Author Contributions: Conceptualization, B.P. and D.J.; methodology, Y.L.; formal analysis, B.P.
and J.Y.; data curation, B.P. and Y.L.; writing—original draft preparation, J.Y.; writing—review and
editing, B.P. and D.J.; supervision, D.J. All authors have read and agreed to the published version of
the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki and approved by the Institutional Review Board of Yonsei University
Gangnam Severance Hospital (2015-32-0009).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the
study.
Data Availability Statement: The data underlying this article will be shared upon reasonable request
from the corresponding author.
Acknowledgments: The authors would like to thank the Korea Health Insurance Review and
Assessment Services (HIRA) for their cooperation.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.Z.; Benjamin,
E.J.; Benziger, C.P.; et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update from the GBD 2019
Study. J. Am. Coll. Cardiol. 2020, 76, 2982–3021. [CrossRef] [PubMed]
2. Naghavi, M.; Abajobir, A.A.; Abbafati, C.; Abbas, K.M.; Abd-Allah, F.; Abera, S.F.; Aboyans, V.; Adetokunboh, O.; Afshin, A.;
Agrawal, A. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for
the global burden of disease study 2016. Lancet 2017, 390, 1151–1210. [CrossRef]
3. Yusuf, S.; Reddy, S.; Ôunpuu, S.; Anand, S. Global burden of cardiovascular diseases: Part i: General considerations, the
epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104, 2746–2753. [CrossRef]
4. Ormazabal, V.; Nair, S.; Elfeky, O.; Aguayo, C.; Salomon, C.; Zuñiga, F.A. Association between insulin resistance and the
development of cardiovascular disease. Cardiovasc. Diabetol. 2018, 17, 122. [CrossRef]
J. Pers. Med. 2021, 11, 742 8 of 9
5. Fahed, M.; Jaoudeh, M.G.A.; Merhi, S.; Mosleh, J.M.B.; Ghadieh, R.; Al Hayek, S.; Fares, J.E.E.H. Evaluation of risk factors for
insulin resistance: A cross sectional study among employees at a private university in Lebanon. BMC Endocr. Disord. 2020, 20,
1–14. [CrossRef]
6. Vafaeimanesh, J.; Parham, M.; Norouzi, S.; Hamednasimi, P.; Bagherzadeh, M. Insulin resistance and coronary artery disease in
non-diabetic patients: Is there any correlation? Casp. J. Intern. Med. 2018, 9, 121–126. [CrossRef]
7. Evans, J.M.M.; Wang, J.; Morris, A.D. Comparison of cardiovascular risk between patients with type 2 diabetes and those who
had had a myocardial infarction: Cross sectional and cohort studies. BMJ 2002, 324, 939. [CrossRef] [PubMed]
8. Lee, C.D.; Folsom, A.R.; Pankow, J.S.; Brancati, F.L. Cardiovascular events in diabetic and nondiabetic adults with or without
history of myocardial infarction. Circulation 2004, 109, 855–860. [CrossRef]
9. Bello-Chavolla, O.Y.; Almeda-Valdes, P.; Gómez-Velasco, D.; Viveros-Ruiz, T.; Cruz-Bautista, I.; Romo-Romo, A.; Sánchez-Lázaro,
D.; Meza-Oviedo, D.; Vargas-Vazquez, A.; Campos, O.A.; et al. METS-IR, a novel score to evaluate insulin sensitivity, is predictive
of visceral adiposity and incident type 2 diabetes. Eur. J. Endocrinol. 2018, 178, 533–544. [CrossRef] [PubMed]
10. Liu, X.Z.; Fan, J.; Pan, S.J. METS-IR, a novel simple insulin resistance indexes, is associated with hypertension in normal-weight
Chinese adults. J. Clin. Hypertens. 2019, 21, 1075–1081. [CrossRef]
11. Park, B.; Lee, Y.-J.; Lee, H.S.; Jung, D.-H. The triglyceride-glucose index predicts ischemic heart disease risk in Koreans: A
prospective study using National Health Insurance Service data. Cardiovasc. Diabetol. 2020, 19, 1–8. [CrossRef] [PubMed]
12. Kim, M.K.; Seung-Hyun Committee of Clinical Practice Guidelines, Korean Diabetes Association; Kim, B.-Y.; Kang, E.S.; Noh, J.;
Kim, S.-K.; Park, S.-O.; Hur, K.Y.; Chon, S.; Moon, M.K.; et al. 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in
Korea. Diabetes Metab. J. 2019, 43, 398–406. [CrossRef]
13. Carretero, O.A.; Oparil, S. Essential hypertension: Part i: Definition and etiology. Circulation 2000, 101, 329–335. [CrossRef]
[PubMed]
14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes
mellitus. Diabetes Care 2003, 26, 3160–3167.
15. Einhorn, D. American College of Endocrinology Position Statement on the Insulin Resistance Syndrome. Endocr. Pract. 2003, 9,
5–21. [CrossRef]
16. Levey, A.S.; Eckardt, K.-U.; Tsukamoto, Y.; Levin, A.; Coresh, J.; Rossert, J.; Zeeuw, D.D.; Hostetter, T.H.; Lameire, N.; Eknoyan, G.
Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes
(KDIGO). Kidney Int. 2005, 67, 2089–2100. [CrossRef] [PubMed]
17. Bornfeldt, K.E.; Tabas, I. Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metabol. 2011, 14, 575–585. [CrossRef]
18. Yanase, M.; Takatsu, F.; Tagawa, T.; Kato, T.; Arai, K.; Koyasu, M.; Horibe, H.; Nomoto, S.; Takemoto, K.; Shimizu, S.; et al. Insulin
Resistance and Fasting Hyperinsulinemia Are Risk Factors for New Cardiovascular Events in Patients with Prior Coronary Artery
Disease and Normal Glucose Tolerance. Circ. J. 2004, 68, 47–52. [CrossRef] [PubMed]
19. Karrowni, W.; Li, Y.; Jones, P.G.; Cresci, S.; Abdallah, M.S.; Lanfear, D.E.; Maddox, T.M.; McGuire, D.K.; Spertus, J.A.; Horwitz, P.A.
Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarction.
Arter. Thromb. Vasc. Biol. 2013, 33, 2245–2251. [CrossRef]
20. Wallace, T.M.; Matthews, D.R. The assessment of insulin resistance in man. Diabet. Med. 2002, 19, 527–534. [CrossRef]
21. Rudvik, A.; Månsson, M. Evaluation of surrogate measures of insulin sensitivity—correlation with gold standard is not enough.
BMC Med. Res. Methodol. 2018, 18, 64. [CrossRef]
22. Manley, S.E.; Stratton, I.; Clark, P.M.; Luzio, S. Comparison of 11 Human Insulin Assays: Implications for Clinical Investigation
and Research. Clin. Chem. 2007, 53, 922–932. [CrossRef] [PubMed]
23. Eeg-Olofsson, K.; Gudbjörnsdottir, S.; Eliasson, B.; Zethelius, B.; Cederholm, J. The triglycerides-to-HDL-cholesterol ratio and
cardiovascular disease risk in obese patients with type 2 diabetes: An observational study from the Swedish National Diabetes
Register (NDR). Diabetes Res. Clin. Pract. 2014, 106, 136–144. [CrossRef] [PubMed]
24. Tatsumi, Y.; Morimoto, A.; Asayama, K.; Sonoda, N.; Miyamatsu, N.; Ohno, Y.; Miyamoto, Y.; Izawa, S.; Ohkubo, T. Fasting Blood
Glucose Predicts Incidence of Hypertension Independent of HbA1c Levels and Insulin Resistance in Middle-Aged Japanese: The
Saku Study. Am. J. Hypertens. 2019, 32, 1178–1185. [CrossRef] [PubMed]
25. Reaven, G.M. Role of insulin resistance in human disease. Diabetes 1988, 37, 1595–1607. [CrossRef]
26. Stout, R.W. Insulin and Atheroma: 20-Yr Perspective. Diabetes Care 1990, 13, 631–654. [CrossRef] [PubMed]
27. Bonora, E.; Targher, G.; Formentini, G.; Calcaterra, F.; Lombardi, S.; Marini, F.; Zenari, L.; Saggiani, F.; Poli, M.; Perbellini, S.; et al.
The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from
the Verona Diabetes Complications Study. Diabet. Med. 2004, 21, 52–58. [CrossRef]
28. Ninomiya, T.; Kubo, M.; Doi, Y.; Yonemoto, K.; Tanizaki, Y.; Rahman, M.; Arima, H.; Tsuryuya, K.; Iida, M.; Kiyohara, Y. Impact of
metabolic syndrome on the development of cardiovascular disease in a general japanese population: The hisayama study. Stroke
2007, 38, 2063–2069. [CrossRef]
29. McNeill, A.M.; Rosamond, W.D.; Girman, C.J.; Golden, S.H.; Schmidt, M.I.; East, H.E.; Ballantyne, C.M.; Heiss, G. The Metabolic
Syndrome and 11-Year Risk of Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study. Diabetes Care
2005, 28, 385–390. [CrossRef]
30. Ford, E.S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the national health
and nutrition examination survey ii mortality study. Atherosclerosis 2004, 173, 307–312. [CrossRef]
J. Pers. Med. 2021, 11, 742 9 of 9
31. Mente, A.; Yusuf, S.; Islam, S.; McQueen, M.J.; Tanomsup, S.; Onen, C.L.; Rangarajan, S.; Gerstein, H.; Anand, S.S. Metabolic
Syndrome and Risk of Acute Myocardial Infarction: A Case-Control Study of 26,903 Subjects From 52 Countries. J. Am. Coll.
Cardiol. 2010, 55, 2390–2398. [CrossRef] [PubMed]
32. Lakka, H.-M.; Laaksonen, D.E.; Lakka, T.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The Metabolic Syndrome
and Total and Cardiovascular Disease Mortality in Middle-aged Men. JAMA 2002, 288, 2709–2716. [CrossRef] [PubMed]
33. Sattar, N.; Gaw, A.; Scherbakova, O.; Ford, I.; O’Reilly, D.S.; Haffner, S.M.; Isles, C.; Macfarlane, P.W.; Packard, C.J.; Cobbe, S.M.;
et al. Metabolic Syndrome with and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the
West of Scotland Coronary Prevention Study. Circulation 2003, 108, 414–419. [CrossRef]
34. Malik, S.; Wong, N.D.; Franklin, S.S.; Kamath, T.V.; L’Italien, G.J.; Pio, J.R.; Williams, G.R. Impact of the Metabolic Syndrome on
Mortality from Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults. Circulation 2004, 110,
1245–1250. [CrossRef] [PubMed]
35. Borg, R.; Kuenen, J.C.; Carstensen, B.; Zheng, H.; Nathan, D.M.; Heine, R.J.; Nerup, J.; Borchjohnsen, K.; Witte, D. HbA1c and
mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or
glucose variability in persons with diabetes: The A1C-Derived Average Glucose (ADAG) study. Diabetology 2010, 54, 69–72.
[CrossRef]
36. Meigs, J.B.; Wilson, P.W.F.; Fox, C.S.; Vasan, R.S.; Nathan, D.M.; Sullivan, L.; D’Agostino, R.B. Body Mass Index, Metabolic
Syndrome, and Risk of Type 2 Diabetes or Cardiovascular Disease. J. Clin. Endocrinol. Metab. 2006, 91, 2906–2912. [CrossRef]
37. St-Pierre, A.C.; Cantin, B.; Mauriège, P.; Bergeron, J.; Dagenais, G.R.; Després, J.-P.; Lamarche, B. Insulin resistance syndrome,
body mass index and the risk of ischemic heart disease. Can. Med. Assoc. J. 2005, 172, 1301–1305. [CrossRef]
38. Chopra, A.K. Metabolic Syndrome or Insulin Resistance: Evolution, Controversies and Association with Cardiovascular Disease
Risk. Indian J. Clin. Cardiol. 2020, 1, 77–85. [CrossRef]
39. Lim, J.; Kim, J.; Koo, S.H.; Kwon, G.C. Comparison of triglyceride glucose index, and related parameters to predict insulin
resistance in Korean adults: An analysis of the 2007-2010 Korean National Health and Nutrition Examination Survey. PLoS ONE
2019, 14, e0212963. [CrossRef]
40. Jin, J.-L.; Cao, Y.-X.; Wu, L.-G.; You, X.-D.; Guo, Y.-L.; Wu, N.-Q.; Zhu, C.-G.; Gao, Y.; Dong, Q.-T.; Zhang, H.-W.; et al. Triglyceride
glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. J. Thorac. Dis. 2018, 10, 6137–6146.
[CrossRef] [PubMed]
41. Collaboration, A.P.C.S. A comparison of lipid variables as predictors of cardiovascular disease in the asia pacific region. Ann.
Epidemiol. 2005, 15, 405–413.
42. Yang, W.; Ma, R.; Zhang, X.; Guo, H.; He, J.; Mao, L.; Mu, L.; Hu, Y.; Yan, Y.; Liu, J.; et al. Comparison Between Metabolic
Syndrome and the Framingham Risk Score as Predictors of Cardiovascular Diseases Among Kazakhs in Xinjiang. Sci. Rep. 2018,
8, 16474. [CrossRef]
43. Liu, J.; Zhao, N.; Wang, W.; Sun, J.-Y.; Liu, J.; Wang, M.; Qin, L.-P.; Wu, Z.-S. Incidence risk of cardiovascular diseases associated
with specific combinations regarding the metabolic syndrome components. Zhonghua Liu Xing Bing Xue Za Zhi 2008, 29, 652–655.
[PubMed]
44. Woodward, M.; Tunstall-Pedoe, H. The metabolic syndrome is not a sensible tool for predicting the risk of coronary heart disease.
Eur. J. Cardiovasc. Prev. Rehabil. 2009, 16, 210–214. [CrossRef] [PubMed]
45. Knuiman, M.W.; Hung, J.; Divitini, M.L.; Davis, T.M.; Beilby, J. Utility of the metabolic syndrome and its components in the
prediction of incident cardiovascular disease: A prospective cohort study. Eur. J. Cardiovasc. Prev. Rehabil. 2009, 16, 235–241.
[CrossRef] [PubMed]
